{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:20:16Z","timestamp":1783434016464,"version":"3.54.6"},"reference-count":55,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":2930,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The dopaminergic treatment represents the primary treatment in prolactinomas, which are the most common pituitary adenomas and account for about 40% of all pituitary tumours with an annual incidence of six to ten cases per million population. The dopaminergic treatment includes ergot and non-ergot derivatives with high affinity for the dopamine receptors D1 or\/and D2. Through the activation of the dopaminergic pathway on pituitary lactotrophs, the dopamine agonists inhibit the prolactin synthesis and secretion, therefore normalizing the prolactin levels and restoring eugonadism, but they also lead to tumour shrinkage. Treatment with dopamine agonists has been associated \u2013 apart from the common side effects such as gastrointestinal symptoms, dizziness and hypotension \u2013 with neuropsychiatric side effects such as impulse control disorders (e.g. pathological gambling, compulsive shopping, hypersexuality and binge eating) and also with behavioral changes from low mood, irritability and verbal aggressiveness up to psychotic and manic symptoms and paranoid delusions not only in patients with prolactinomas but also in patients with Parkinson\u2019s disease and restless leg syndrome. They usually have de novo onset after initiation of the dopaminergic treatment and have been mainly reported in patients with Parkinson\u2019s disease, who are being treated with higher doses of dopamine agonists. Moreover, dopamine and prolactin seem to play an essential role in the metabolic pathway. Patients with hyperprolactinemia tend to have increased body weight and an altered metabolic profile with hyperinsulinemia and increased prevalence of diabetes mellitus in comparison to healthy individuals and patients with non-functioning pituitary adenomas. Treatment with dopamine agonists in these patients in short-term studies seems to lead to weight loss and amelioration of the metabolic changes. Together these observations provide evidence that dopamine and prolactin have a crucial role both in the regard and metabolic system, findings that merit further investigation in long-term studies.<\/jats:p>","DOI":"10.1530\/ec-18-0030","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T20:35:20Z","timestamp":1517258120000},"page":"R88-R94","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":23,"title":["Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist"],"prefix":"10.1530","volume":"7","author":[{"given":"Anastasia P","family":"Athanasoulia-Kaspar","sequence":"first","affiliation":[{"name":"Max Planck Institute of Psychiatry","department":["Department of Internal Medicine, Endocrinology and Clinical Chemistry, Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin H","family":"Popp","sequence":"additional","affiliation":[{"name":"Max Planck Institute of Psychiatry","department":["Department of Internal Medicine, Endocrinology and Clinical Chemistry, Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter Karl","family":"Stalla","sequence":"additional","affiliation":[{"name":"Max Planck Institute of Psychiatry","department":["Department of Internal Medicine, Endocrinology and Clinical Chemistry, Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2026070710091416800_bib1","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(09)70287-X","article-title":"Chronic dopaminergic stimulation in Parkinson\u2019s disease: from dyskinesias to impulse control disorders","volume":"8","author":"Voon","year":"2009","journal-title":"Lancet Neurology"},{"key":"2026070710091416800_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","article-title":"Impulse control disorders and levodopa-induced dyskinesias in Parkinson\u2019s disease: an update","volume":"16","author":"Voon","year":"2017","journal-title":"Lancet Neurology"},{"key":"2026070710091416800_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/01.WNL.0000076478.45005.EC","article-title":"Pathological gambling associated with dopamine agonist therapy in Parkinson\u2019s disease","volume":"61","author":"Driver-Dunckley","year":"2003","journal-title":"Neurology"},{"key":"2026070710091416800_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0025-6196(11)60538-7","article-title":"Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease","volume":"84","author":"Bostwick","year":"2009","journal-title":"Mayo Clinic Proceedings"},{"key":"2026070710091416800_bib5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/mds.20757","article-title":"Compulsive eating and weight gain related to dopamine agonist use","volume":"21","author":"Nirenberg","year":"2006","journal-title":"Movement Disorders"},{"key":"2026070710091416800_bib6","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","article-title":"Prospective prevalence of pathologic gambling and medication association in Parkinson disease","volume":"66","author":"Voon","year":"2006","journal-title":"Neurology"},{"key":"2026070710091416800_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Archives of Neurology"},{"key":"2026070710091416800_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diacare.19.6.667","article-title":"Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects","volume":"19","author":"Cincotta","year":"1996","journal-title":"Diabetes Care"},{"key":"2026070710091416800_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/WNF.0b013e31820d6699","article-title":"The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome","volume":"34","author":"Dang","year":"2011","journal-title":"Clinical Neuropharmacology"},{"key":"2026070710091416800_bib10","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep"},{"key":"2026070710091416800_bib11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rbp.2012.03.001","article-title":"Lifetime prevalence, age and gender distribution and age-of-onset of psychiatric disorders in the Sao Paulo Metropolitan Area, Brazil: results from the Sao Paulo Megacity Mental Health Survey","volume":"34","author":"Viana","year":"2012","journal-title":"Revista Brasileira de Psiquiatria"},{"key":"2026070710091416800_bib12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clinical Endocrinology"},{"key":"2026070710091416800_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5694\/j.1326-5377.2009.tb02289.x","article-title":"Pathological gambling and hypersexuality in cabergoline-treated prolactinoma","volume":"190","author":"Falhammar","year":"2009","journal-title":"Medical Journal of Australia"},{"key":"2026070710091416800_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","article-title":"Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma","volume":"19","author":"Davie","year":"2007","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"2026070710091416800_bib15","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0031-1281580","article-title":"Pathological gambling induced by dopamine agonists","volume":"79","author":"Gahr","year":"2011","journal-title":"Fortschritte der Neurologie-Psychiatrie"},{"key":"2026070710091416800_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova","year":"2011","journal-title":"Clinical Neuropharmacology"},{"key":"2026070710091416800_bib17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/cen.13339","article-title":"Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma","volume":"86","author":"Bulwer","year":"2017","journal-title":"Clinical Endocrinology"},{"key":"2026070710091416800_bib18","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"key":"2026070710091416800_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/WNF.0b013e31829fc165","article-title":"Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma","volume":"36","author":"Thondam","year":"2013","journal-title":"Clinical Neuropharmacology"},{"key":"2026070710091416800_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psym.2012.10.002","article-title":"Dopamine agonist-induced impulse control disorders in a patient with prolactinoma","volume":"54","author":"Almanzar","year":"2013","journal-title":"Psychosomatics"},{"key":"2026070710091416800_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00207458708987147","article-title":"Acute psychosis in a woman with a prolactinoma","volume":"37","author":"Sandyk","year":"1987","journal-title":"International Journal of Neuroscience"},{"key":"2026070710091416800_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","article-title":"Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance","volume":"75","author":"Marzolini","year":"2004","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"2026070710091416800_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1530\/EJE-12-0198","article-title":"Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas","volume":"167","author":"Athanasoulia","year":"2012","journal-title":"European Journal of Endocrinology"},{"key":"2026070710091416800_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2377-9-23","article-title":"Dopamine agonists and their risk to induce psychotic episodes in Parkinson\u2019s disease: a case-control study","volume":"9","author":"Ecker","year":"2009","journal-title":"BMC Neurology"},{"key":"2026070710091416800_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/2045125315626345","article-title":"Cabergoline-induced manic episode: case report","volume":"6","author":"Yuksel","year":"2016","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"2026070710091416800_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1176\/appi.neuropsych.16110313","article-title":"Clozapine treatment for cabergoline-induced psychosis in a patient with a giant prolactinoma","volume":"29","author":"Perez-Esparza","year":"2017","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"2026070710091416800_bib27","doi-asserted-by":"crossref","first-page":"150100","DOI":"10.1530\/EDM-15-0100","article-title":"Management of a microprolactinoma with aripiprazole in a woman with cabergoline-induced mania","volume":"2015","author":"Burback","year":"2015","journal-title":"Endocrinology, Diabetes and Metabolism Case Reports"},{"key":"2026070710091416800_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajp.2016.05.010","article-title":"Cabergoline can induce mania with psychotic features in bipolar I disorder: a case report","volume":"22","author":"Rovera","year":"2016","journal-title":"Asian Journal of Psychiatry"},{"key":"2026070710091416800_bib29","doi-asserted-by":"crossref","first-page":"160028","DOI":"10.1530\/EDM-16-0028","article-title":"Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole","volume":"2016","author":"Bakker","year":"2016","journal-title":"Endocrinology, Diabetes and Metabolism Case Reports"},{"key":"2026070710091416800_bib30","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"2026070710091416800_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/PL00007539","article-title":"Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder","volume":"250","author":"Melkersson","year":"2000","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"2026070710091416800_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","article-title":"Treating prolactinomas with dopamine agonists: always worth the gamble?","volume":"51","author":"Noronha","year":"2016","journal-title":"Endocrine"},{"key":"2026070710091416800_bib33","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0033-3182(10)70718-0","article-title":"Management of psychosis associated with a prolactinoma: case report and review of the literature","volume":"51","author":"Ali","year":"2010","journal-title":"Psychosomatics"},{"key":"2026070710091416800_bib34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1365-2265.2006.02656.x","article-title":"The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapy","volume":"65","author":"Schmid","year":"2006","journal-title":"Clinical Endocrinology"},{"key":"2026070710091416800_bib35","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2265.2006.02469.x","article-title":"The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy","volume":"64","author":"Serri","year":"2006","journal-title":"Clinical Endocrinology"},{"key":"2026070710091416800_bib36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4414\/smw.2006.10955","article-title":"Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma","volume":"136","author":"Schmid","year":"2006","journal-title":"Swiss Medical Weekly"},{"key":"2026070710091416800_bib37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels","volume":"48","author":"Greenman","year":"1998","journal-title":"Clinical Endocrinology"},{"key":"2026070710091416800_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/oby.2003.46","article-title":"Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia","volume":"11","author":"Korner","year":"2003","journal-title":"Obesity Research"},{"key":"2026070710091416800_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11102-010-0277-9","article-title":"Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy","volume":"14","author":"Berinder","year":"2011","journal-title":"Pituitary"},{"key":"2026070710091416800_bib40","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/oby.2010.150","article-title":"BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists","volume":"19","author":"dos Santos Silva","year":"2011","journal-title":"Obesity"},{"key":"2026070710091416800_bib41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/cen.12204","article-title":"Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels","volume":"79","author":"Ciresi","year":"2013","journal-title":"Clinical Endocrinology"},{"key":"2026070710091416800_bib42","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2265.2002.01510.x","article-title":"Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas?","volume":"56","author":"Yermus","year":"2002","journal-title":"Clinical Endocrinology"},{"key":"2026070710091416800_bib43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/2230-8210.176346","article-title":"Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: response to treatment with cabergoline","volume":"20","author":"Pala","year":"2016","journal-title":"Indian Journal of Endocrinology and Metabolism"},{"key":"2026070710091416800_bib44","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11102-013-0496-y","article-title":"The effect of the ANKK1\/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas","volume":"17","author":"Athanasoulia","year":"2014","journal-title":"Pituitary"},{"key":"2026070710091416800_bib45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5152\/jtgga.2015.15015","article-title":"Hyperprolactinemia has no effect on plasma ghrelin levels in patients with prolactinoma","volume":"16","author":"Delibasi","year":"2015","journal-title":"Journal of the Turkish-German Gynecological Association"},{"key":"2026070710091416800_bib46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pcd.2015.10.008","article-title":"A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters","volume":"10","author":"Lamos","year":"2016","journal-title":"Primary Care Diabetes"},{"key":"2026070710091416800_bib47","first-page":"390","article-title":"Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure","volume":"67","author":"Taghavi","year":"2012","journal-title":"Medical Journal of Malaysia"},{"key":"2026070710091416800_bib48","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1463-1326.2011.01534.x","article-title":"Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults","volume":"14","author":"Gibson","year":"2012","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"2026070710091416800_bib49","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0026-0495(91)90057-4","article-title":"Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus","volume":"40","author":"Cincotta","year":"1991","journal-title":"Metabolism: Clinical and Experimental"},{"key":"2026070710091416800_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000054344","article-title":"Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters","volume":"68","author":"Luo","year":"1998","journal-title":"Neuroendocrinology"},{"key":"2026070710091416800_bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/eje.0.1470077","article-title":"Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine","volume":"147","author":"Doknic","year":"2002","journal-title":"European Journal of Endocrinology"},{"key":"2026070710091416800_bib52","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1365-2265.2007.02973.x","article-title":"Body fat in nonobese women with prolactinoma treated with dopamine agonists","volume":"67","author":"Naliato","year":"2007","journal-title":"Clinical Endocrinology"},{"key":"2026070710091416800_bib53","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000335996","article-title":"Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls","volume":"96","author":"Athanasoulia","year":"2012","journal-title":"Neuroendocrinology"},{"key":"2026070710091416800_bib54","doi-asserted-by":"crossref","first-page":"e25537","DOI":"10.1371\/journal.pone.0025537","article-title":"Dopamine receptors in human adipocytes: expression and functions","volume":"6","author":"Borcherding","year":"2011","journal-title":"PLoS ONE"},{"key":"2026070710091416800_bib55","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1007\/s11033-012-2455-5","article-title":"Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on alpha2-adrenergic receptor in 3T3-L1 adipocyte cells","volume":"40","author":"Mukherjee","year":"2013","journal-title":"Molecular Biology Reports"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/7\/2\/EC-18-0030.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/7\/2\/R88\/1517\/ec-18-0030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/7\/2\/R88\/1517\/ec-18-0030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:09:24Z","timestamp":1783433364000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/7\/2\/R88\/258\/Neuropsychiatric-and-metabolic-aspects-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-18-0030","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,1]]}}}